tiprankstipranks
Trending News
More News >

Pfizer price target raised to $30 from $28 at Barclays

Barclays analyst Carter Gould raised the firm’s price target on Pfizer to $30 from $28 and keeps an Equal Weight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue